factor Xa


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to factor Xa: factor IIa

fac·tor Xa

(fak'tŏr)
The active form of factor X; it is formed from factor X by limited proteolysis via factor VIIa and tissue factor (extrinsic pathway) or factor IXa, VIIIa (intrinsic pathway). Factor Xa forms a complex with factor Va, phospholipid, and calcium to convert prothrombin to thrombin.
References in periodicals archive ?
Perzborn, Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl} methyl) thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Rivaroxaban is an oxazolidinone derivative that inhibits factor Xa and interrupts both the extrinsic and intrinsic coagulation pathways, thereby inhibiting thrombin formation.
In conclusion, our data demonstrate similar mortality and neurological outcomes and no venous thromboembolic events for patients with factor Xa inhibitor- and VKA-associated ICH treated with 4F-PCC.
Subsequently, there has been fast-tracking for FDA approval of another 2 candidate medications for reversal of factor Xa inhibitors, andexanet-a and ciraparantag, and the latter can also reverse the anticoagulant effects of unfractionated heparin and lowmolecular weight heparin, in addition to that of the factor Xa inhibitors (Table 2).
Another DOAC, factor Xa inhibitor, did not increase the concentration of free hemoglobin in either brain compartment, but there was a trend in increased free hemoglobin in the cerebellum (Figure 2).
Patients received 3 days of factor Xa inhibition and then, again using randomization, received either intravenous andexanet alfa or placebo.
The guidelines advise clinicians to evaluate renal function prior to starting any direct thrombin or factor Xa inhibitors, and to reevaluate at least annually and when clinically indicated.
Rivaroxaban, apixaban and edoxaban are very specific antagonists of activated factor Xa, which directly converts prothrombin to thrombin, thus leading to clot formation.
Rivaroxaban is an oral, direct Factor Xa inhibitor that has been developed in recent years.
It is also employed during extracorporeal circulation (vascular surgery and hemodialysis), exhibiting anticoagulant action mainly through potentiation of AT, a serine protease inhibitor (serpin) which controls the coagulation process, especially thrombin and factor Xa (NADER et al., 2001; QUINSEY et al., 2004).
Fondaparinux, an indirect factor Xa inhibitor (via antithrombin), can be used instead of LMWHs, such as enoxaparin.